AU2020412201A1 - TGF-beta-RII binding proteins - Google Patents

TGF-beta-RII binding proteins Download PDF

Info

Publication number
AU2020412201A1
AU2020412201A1 AU2020412201A AU2020412201A AU2020412201A1 AU 2020412201 A1 AU2020412201 A1 AU 2020412201A1 AU 2020412201 A AU2020412201 A AU 2020412201A AU 2020412201 A AU2020412201 A AU 2020412201A AU 2020412201 A1 AU2020412201 A1 AU 2020412201A1
Authority
AU
Australia
Prior art keywords
antibody
seq
amino acid
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020412201A
Other languages
English (en)
Inventor
Cornelius Adriaan De Kruif
Rinse KLOOSTER
Mark Throsby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus BV
Original Assignee
Merus BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus BV filed Critical Merus BV
Publication of AU2020412201A1 publication Critical patent/AU2020412201A1/en
Priority to AU2023200779A priority Critical patent/AU2023200779A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020412201A 2019-12-24 2020-12-22 TGF-beta-RII binding proteins Pending AU2020412201A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023200779A AU2023200779A1 (en) 2019-12-24 2023-02-13 TGF-beta-RII binding proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2024576 2019-12-24
NL2024576 2019-12-24
PCT/NL2020/050813 WO2021133167A1 (en) 2019-12-24 2020-12-22 Tgf-beta-rii binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200779A Division AU2023200779A1 (en) 2019-12-24 2023-02-13 TGF-beta-RII binding proteins

Publications (1)

Publication Number Publication Date
AU2020412201A1 true AU2020412201A1 (en) 2022-07-14

Family

ID=69700252

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020412201A Pending AU2020412201A1 (en) 2019-12-24 2020-12-22 TGF-beta-RII binding proteins
AU2023200779A Pending AU2023200779A1 (en) 2019-12-24 2023-02-13 TGF-beta-RII binding proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023200779A Pending AU2023200779A1 (en) 2019-12-24 2023-02-13 TGF-beta-RII binding proteins

Country Status (14)

Country Link
US (1) US20250270331A1 (enExample)
EP (2) EP4269433A3 (enExample)
JP (3) JP7633259B2 (enExample)
KR (2) KR20230145542A (enExample)
CN (3) CN116375869A (enExample)
AR (2) AR120914A1 (enExample)
AU (2) AU2020412201A1 (enExample)
BR (1) BR112022012522A2 (enExample)
CA (1) CA3165605A1 (enExample)
IL (2) IL294181A (enExample)
MX (2) MX2022007919A (enExample)
PH (1) PH12022551527A1 (enExample)
TW (2) TW202417513A (enExample)
WO (1) WO2021133167A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3231649A1 (en) * 2021-11-19 2023-05-25 Cecilia Anna Wilhelmina Geuijen Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
EP4638501A1 (en) 2022-12-20 2025-10-29 Merus N.V. Fap binding domains and bispecific binding moieties that bind fap and tgf-beta rii

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
ES2445193T3 (es) 2008-06-27 2014-02-28 Merus B.V. Mamíferos no humanos productores de anticuerpos
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
CA2823104A1 (en) 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
PT2900694T (pt) 2012-09-27 2018-11-13 Merus Nv Anticorpos de igg biespecíficos como ativadores de células t
JP2018527903A (ja) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody

Also Published As

Publication number Publication date
JP7633259B2 (ja) 2025-02-19
KR20230145542A (ko) 2023-10-17
MX2022007919A (es) 2022-07-27
AR120914A1 (es) 2022-03-30
IL304317A (en) 2023-09-01
JP2023508202A (ja) 2023-03-01
TW202417513A (zh) 2024-05-01
TW202128747A (zh) 2021-08-01
JP2025083342A (ja) 2025-05-30
AR130991A2 (es) 2025-02-05
CA3165605A1 (en) 2021-07-01
JP2023076596A (ja) 2023-06-01
MX2024002182A (es) 2024-05-03
US20250270331A1 (en) 2025-08-28
CN116199780A (zh) 2023-06-02
PH12022551527A1 (en) 2024-01-29
KR20220117267A (ko) 2022-08-23
CN116375869A (zh) 2023-07-04
IL294181A (en) 2022-08-01
CN115038497A (zh) 2022-09-09
BR112022012522A2 (pt) 2022-09-06
AU2023200779A1 (en) 2023-03-09
WO2021133167A1 (en) 2021-07-01
EP4269433A2 (en) 2023-11-01
EP4269433A3 (en) 2024-05-22
EP4081306A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
CN110606891B (zh) 一种针对人cldn18.2的抗体分子，抗原结合片段及其医药用途
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN112912397A (zh) 抗cd3抗体及其用途
JP7554309B2 (ja) 抗ｃｄ１４７抗体
EP4378954A1 (en) Anti-pvrig/anti-tigit bispecific antibody and application
CN110790839B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
JP2025083342A (ja) ＴＧＦ－βＲＩＩ結合タンパク質
JP7352007B2 (ja) ヒト化抗ｖｅｇｆモノクローナル抗体
WO2021013061A1 (zh) 一种人源化抗vegfr2抗体及其应用
CN118076638A (zh) 新型抗sirpa抗体
CA3120059A1 (en) Anti-periostin antibodies and uses thereof
CN113637075A (zh) 双特异性抗原结合分子及其医药用途
JP7538552B2 (ja) Ｌｉｆに特異的な結合分子及びその使用
CN114340668A (zh) 结合于cd38和cd3的异源二聚抗体
HK40094429A (en) Tgf-beta-rii binding proteins
BR122023027661A2 (pt) Proteínas de ligação de tgf-beta-rii
RU2809746C2 (ru) Гуманизированное моноклональное антитело против vegf
TW202436350A (zh) 抗ｌｉｌｒｂ１及／或抗ｌｉｌｒｂ２抗體及其等用途
HK40066221B (zh) 人源化抗vegf fab抗体片段及其用途
HK40066221A (zh) 人源化抗vegf fab抗体片段及其用途
HK40066231B (zh) 人源化抗vegf单克隆抗体
HK40066231A (zh) 人源化抗vegf单克隆抗体
HK40052977A (en) Anti-cd3 antibodies and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ THROSBY, MARK; KLOOSTER, RINSE AND DE KRUIF, CORNELIUS ADRIAAN